Daily News
Daily News

Protective effect of piceatannol against acute lung injury explored

Respiratory Therapeutics Daily News

2020 SEP 21 (NewsRx) -- By a News Reporter-Staff News Editor at Respiratory Therapeutics Daily News -- Investigators publish new report on Lung Diseases and Conditions - Acute Lung Injury. According to news reporting originating in Changchun, People’s Republic of China, by NewsRx journalists, research stated, “Acute lung injury (ALI) is a common and complex inflammatory lung syndrome with higher morbidity and mortality rate. Piceatannol (PIC) has anti-inflammation and anti-oxidant properties.”

Financial support for this research came from National Natural Science Foundation of China.

The news reporters obtained a quote from the research from Jilin University, “The study was designed to explore the effect and the action mechanisms of PIC on lipopolysaccharide (LPS)-induced ALI. Twenty-four hours after LPS challenge, mice from different treatment groups were euthanized, and the bronchoalveolar lavage fluid (BALF) and lung tissue samples were collected. Then the degree of pulmonary edema, lung pathological changes, myeloperoxidase (MPO) activity, and the production of pro-inflammatory cytokines were detected. Additionally, the messenger RNA (mRNA) expressions associated with cell adhesion molecules and tight junction were analyzed through quantitative real-time (qRT)-PCR, and the TLR4/NF-kappa B activation was examined by western blot. The results showed that PIC significantly inhibited LPS-induced lung edema, histopathological damage, MPO activity, cell infiltration, and pro-inflammatory cytokines production. Moreover, PIC notably suppressed mRNA expressions associated with inflammation and cell adhesion molecules. Furthermore, PIC also alleviated LPS-induced damage of air-blood barrier through reducing the levels of total proteins in BALF and recovering the expression of occludin and ZO-1 in the lung tissues. We also found that PIC remarkably restrained the LPS-induced TLR4/NF-kappa B pathway activation in lung tissues.”

According to the news reporters, the research concluded: “PIC may be potential to treat LPS-induced acute lung injury (ALI) via regulating air-blood barrier and TLR4/NF-kappa B signaling pathway activation.”

For more information on this research see: Protective Effect of Piceatannol Against Acute Lung Injury Through Protecting the Integrity of Air-blood Barrier and Modulating the Tlr4/nf-kappa B Signaling Pathway Activation. Frontiers in Pharmacology, 2020;10():. Frontiers in Pharmacology can be contacted at: Frontiers Media Sa, Avenue Du Tribunal Federal 34, Lausanne, Ch-1015, Switzerland.

Our news correspondents report that additional information may be obtained by contacting Ben-Dong Fu, Jilin University, College of Veterinary Medicine, Changchun, People’s Republic of China. Additional authors for this research include Lu-Yuan Peng, Meng Yuan, Hai-Tao Shi, Jing-He Li, Ke Song, Jiang-Ni Huang, Peng-Fei Yi and Hai-Qing Shen.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.3389/fphar.2019.01613. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)